Leukemia

Preventing Tumor Lysis Syndrome in Patients Receiving Venetoclax

Preventing Tumor Lysis Syndrome in Patients Receiving Venetoclax

By

What precautions should be taken to prevent tumor lysis syndrome (TLS) in patients receiving venetoclax (Venclexta)?

Fecal Occult Blood Test, Colonoscopy Useful for Detecting Dasatinib-induced Colitis

Fecal Occult Blood Test, Colonoscopy Useful for Detecting Dasatinib-induced Colitis

By

Researchers examined the frequency of TKI-induced hemorrhagic colitis among patients with CML treated with dasatinib and evaluated the efficacy of screening with a fecal occult blood test followed by colonoscopy in this patient population.

Lipid-lowering Drugs May Confer Survival Benefit in Chronic Lymphocytic Leukemia

Lipid-lowering Drugs May Confer Survival Benefit in Chronic Lymphocytic Leukemia

By

Abnormal lipid metabolism is observed in patients with CLL, prompting an investigation to determine if prevalence of metabolic syndrome is higher in patients with CLL and whether lipid-lowering medications impact survival.

ROR1 Expression May Enhance Disease Progression in CLL

ROR1 Expression May Enhance Disease Progression in CLL

By

Expression of ROR1 could promote leukemia-cell activation and enhance disease progression in patients with chronic lymphocytic leukemia, according to a study.

Ibrutinib Effective as Salvage Therapy in Relapsed CLL Following Allogeneic HSCT

Ibrutinib Effective as Salvage Therapy in Relapsed CLL Following Allogeneic HSCT

By

A report of an evaluation of the benefit of ibrutinib in relapsed CLL following allogeneic HSCT based on an analysis of data from patients with relapsed CLL who received ibrutinib salvage therapy after allogeneic HSCT.

5-parameter Prognostic Index Useful for Predicting TTFT, OS in CLL

5-parameter Prognostic Index Useful for Predicting TTFT, OS in CLL

By

In an observational study of an independent cohort of patients with Binet stage A CLL, researchers sought to validate the ability of the CLL International Prognostic Index to predict time to first treatment (TTFT) and overall survival in patients with early-stage disease.

Study Identifies Factors Associated With Infection-related Complications in ALL

Study Identifies Factors Associated With Infection-related Complications in ALL

By

Data on neutropenia and infection-related complications in patients with ALL are lacking; therefore, this study focused on identifying the characteristics and risk factors of infection-related complications in children with newly diagnosed ALL.

Levofloxacin Prophylaxis May Reduce Infection Rate in Relapsed/Refractory AML

Levofloxacin Prophylaxis May Reduce Infection Rate in Relapsed/Refractory AML

By

This study evaluated whether antibacterial prophylaxis effectively reduced the rate of infections overall for patients receiving intensive chemotherapy for relapsed/refractory AML.

Internalizing, Externalizing Behavioral Problems a Significant Postdiagnosis Concern in Children With Cancer

Internalizing, Externalizing Behavioral Problems a Significant Postdiagnosis Concern in Children With Cancer

By

Children with cancer are at risk for developing behavioral problems after diagnosis.

Chronic Lymphocytic Leukemia (Fact Sheet)

Chronic Lymphocytic Leukemia (Fact Sheet)

This fact sheet reviews the incidence and survival statistics of chronic lymphocytic leukemia.

Cost of TKI Therapy Leads to Delay in Treatment for Many Patients With Leukemia

By

Patients with cancer incur significant out-of-pocket costs before their Medicare drug benefits activate, and due to those costs, many patients with CML delayed starting their treatment.

Economic Evaluation of Obinutuzumab in Combination With Chlorambucil in First-line Treatment of Patients With Chronic Lymphocytic Leukemia in Spain

Economic Evaluation of Obinutuzumab in Combination With Chlorambucil in First-line Treatment of Patients With Chronic Lymphocytic Leukemia in Spain

[ClinicoEconomics and Outcomes Research] This research examines the cost-effectiveness of obinutuzumab in combination with chlorambucil (GClb) versus rituximab plus chlorambucil (RClb) in the treatment of previously untreated chronic lymphocytic leukemia.

MRD Assessment Improves PFS Prediction in Patients With CLL

MRD Assessment Improves PFS Prediction in Patients With CLL

By

Assessment of minimal residual disease (MRD) improves the prediction of progression-free survival benefit in patients with CLL who achieve either a complete response or a partial response PR.

Ofatumumab With Fludarabine, Cyclophosphamide Approved for Relapsed CLL

Ofatumumab With Fludarabine, Cyclophosphamide Approved for Relapsed CLL

By

The US Food and Drug Administration has approved ofatumumab in combination with fludarabine and cyclophosphamide for the treatment of relapsed chronic lymphocytic leukemia (CLL).

Study Affirms Activity of Ibrutinib in Patients With R/R CLL With 17p Deletion

Study Affirms Activity of Ibrutinib in Patients With R/R CLL With 17p Deletion

By

Treatment with ibrutinib is associated with a high overall response rate in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and 17p deletion.

Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response

Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response

By

In patients with chronic myeloid leukemia in chronic phase, prolonged treatment with imatinib helps to achieve a deeper molecular response over 5 years.

TKI-intolerant Patients With CLL Can Successfully Receive an Alternate TKI

TKI-intolerant Patients With CLL Can Successfully Receive an Alternate TKI

By

Patients with chronic lymphocytic leukemia (CLL) who discontinue TKI therapy due to toxicity can successfully be treated with an alternate TKI.

Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia

Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia

By

Inhibition of the protein Ezh2 causes chronic myelogenous leukemia (CML) stem cells to die. Adding drugs that target this protein to imatinib (Gleevec) or other BCR-ABL blockers could result in a cure for this disease.

Pregnancy Screening Inconsistent in Female Adolescents Before Chemotherapy Exposure

Pregnancy Screening Inconsistent in Female Adolescents Before Chemotherapy Exposure

By

Pregnancy screening rates before teratogenic exposures are low for female adolescent patients with acute leukemia and those with ER visits including abdominal/pelvic CT.

Immune Cells Are Biologically Older After Hematopoietic Cell Transplantation

Immune Cells Are Biologically Older After Hematopoietic Cell Transplantation

By

Hematopoietic stem cell transplantation (HCT) is found to increase expression of a genetic code used to make proteins, leading to a biological aging of immune cells equivalent to 30 years of chronological age.

Vitamin C Enhances Epigenetic Treatments in Acute Myeloid Leukemia and Myeloid Dysplastic Syndrome

Vitamin C Enhances Epigenetic Treatments in Acute Myeloid Leukemia and Myeloid Dysplastic Syndrome

By

Research using cancer cell lines demonstrated that supplementing standard epigenetic therapy with vitamin C enhanced the drug's antineoplastic action.

EUTOS Registry Represents Benchmark for Evaluation of New CML Treatments

EUTOS Registry Represents Benchmark for Evaluation of New CML Treatments

By

The population-based EUTOS registry demonstrated high overall and progression-free survival rates among patients with chronic myeloid leukemia.

Bone Marrow vs Bloodstream: Stem Cell Source Influences Transplantation Outcomes

Bone Marrow vs Bloodstream: Stem Cell Source Influences Transplantation Outcomes

By

Blood stem cells derived from donor bone marrow resulted in better self-reported psychological well-being and fewer GVHD symptoms.

CML-CP: Dasatinib, Nilotinib Associated With Similar Survival Outcomes as Frontline Therapy

CML-CP: Dasatinib, Nilotinib Associated With Similar Survival Outcomes as Frontline Therapy

By

Dasatinib and nilotinib are associated with similar response rates and survival outcomes in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP).

Social Support Crucial for Patients With CML Receiving Lifelong Targeted Therapy

Social Support Crucial for Patients With CML Receiving Lifelong Targeted Therapy

By

For patients with chronic myeloid leukemia treated with lifelong targeted therapies, social support is crucial for maintaining psychological well-being.

Hyper-CVAD + Ponatinib May Be Superior to Hyper-CVAD + Dasatinib in Ph+ ALL

By

Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) plus ponatinib appears to be superior to hyper-CVAD plus dasatinib for the frontline treatment of patients with Philadelphia chromosome-positive ALL.

Novel Therapies Needed to Improve TP53-mutant AML Outcomes

By

Patients with acute myeloid leukemia (AML) harboring mutations in the TP53 gene have worse complete remission rates and durations and overall survival regardless of age or the type of treatment received.

Tyrosine Kinase Inhibitor Therapy Can Be Safely Stopped in Select Patients With CML in Chronic Phase

Tyrosine Kinase Inhibitor Therapy Can Be Safely Stopped in Select Patients With CML in Chronic Phase

By

A high percentage of patients with CML treated with TKIs achieve deep molecular responses and can safely stop therapy. Initials results of the EURO-SKI trial define prognostic markers that indicate durability of deep molecular responses after stopping TKI therapy.

Monoclonal Antibody Shows Promise in Aggressive R/R Adult T-cell Leukemia/Lymphoma

Monoclonal Antibody Shows Promise in Aggressive R/R Adult T-cell Leukemia/Lymphoma

By

Mogamulizumab induced an encouraging response rate in patients with relapsed/refractory adult T-cell leukemia/lymphoma.

Telomere Length Predicts Risk for Delayed Recovery in Pediatric Patients With AML

Telomere Length Predicts Risk for Delayed Recovery in Pediatric Patients With AML

By

Telomere length is predictive for determining which children treated for AML are at highest risk for delayed recovery, a finding that may have significant implications for treatment-related morbidity and mortality.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs